Side-by-side · Research reference
IGF-DESvsSS-31
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED8/60 cited
BPhase 3HUMAN-REVIEWED9/43 cited
IGF-DES
IGF-1 Analogue · Truncated N-Terminal
~10×Potency vs IGF-1
ReducedIGFBP binding
ResearchStatus
Injection (local or systemic) · Research protocols onlyBredehöft 2008
SS-31
Cardiolipin-binding · Mitochondrial protective
SQ · Abdomen · Once daily
01Mechanism of Action
Parameter
IGF-DES
SS-31
Primary target
IGF-1 receptor (IGF1R)Shields 2007
Cardiolipin in inner mitochondrial membraneSzeto 2014
Pathway
IGF1R activation → PI3K/Akt & MAPK signaling → protein synthesis, proliferation
Cardiolipin binding → cristae stabilisation → ETC integrity → reduced ROS + preserved ATP synthesisSzeto 2014Szilagyi 2009
Downstream effect
Enhanced muscle protein synthesis, myoblast differentiation, reduced apoptosis, cell proliferation
Mitochondrial bioenergetic preservation; cardio-, neuro-, and reno-protective effects in animal + clinical studiesSzeto 2014
Feedback intact?
Unknown — no human endocrine feedback data
—
Origin
Synthetic truncation of native IGF-1 — removal of N-terminal Gly-Pro-Glu tripeptideBredehöft 2008
Synthetic tetrapeptide D-Arg-Dmt-Lys-Phe-NH₂; cell-permeable, mitochondrial-selectiveSzeto 2014
Antibody development
—
—
02Dosage Protocols
Parameter
IGF-DES
SS-31
Research dose range
10–100 ng/mL (in vitro); μg doses (animal models)
Highly context-dependent; no standardized human protocol.
—
Route
Subcutaneous or intramuscular (local injection favored)
Local delivery maximizes tissue-specific uptake.
—
Frequency
Variable — daily to multiple times daily in research
Once daily
Evidence basis
Animal models + in vitro only
Multiple Phase 3 trials (Barth, AMD, ischemia-reperfusion)Szeto 2014Szilagyi 2009
Human data
None — no clinical trials
—
Half-life
Shorter than IGF-1 due to reduced IGFBP binding
Rapid tissue uptake, limited systemic circulation.
~3 h plasma; tissue uptake longer
Standard dose
—
40 mg / day SQ (clinical trials)Szeto 2014
Anecdotal community range 5-10 mg/day. Phase 3 trials use 40 mg.
Lower / starter dose
—
5 mg / day (anecdotal)
Duration
—
Indefinite for mitochondrial disease; cycled for healthspan use
Reconstitution
—
Bacteriostatic water
Timing
—
Morning fasted preferred; pre-workout for exercise-induced mitochondrial stress
03Metabolic / Fat Loss Evidence
Parameter
IGF-DES
SS-31
Primary mechanism
Indirect via muscle hypertrophy → metabolic rate elevation
—
Direct lipolysis
Minimal evidence — IGF-1 axis primarily anabolic, not lipolytic
—
Prostate model
Inhibited BPH cell proliferation when combined with vitamin D3 analogueCrescioli 2002
Context-specific anti-proliferative effect, not fat loss.
—
04Side Effects & Safety
Parameter
IGF-DES
SS-31
Hypoglycemia risk
Theoretical — IGF-1 axis enhances glucose uptake
—
Mitogenic risk
Chronic IGF-1 receptor activation may promote cell proliferation, potential tumor growthCrescioli 2002
—
Injection site reaction
Expected — erythema, irritation, local swelling
Erythema, mild pruritus
Edema / Fluid retention
Possible via sodium retention (IGF-1 axis effect)
—
Human safety data
Absent — no human trials, all effects theoretical or extrapolated
—
Unknown long-term effects
No chronic dosing studies in humans; endocrine, metabolic consequences unknown
—
GI symptoms
—
Nausea (uncommon)
Headache
—
Reported in some Phase 3 trials
Cardiovascular
—
Cardio-protective in studies; no signal of harm
Pregnancy / OB
—
Avoid — insufficient data
Absolute Contraindications
IGF-DES
- ·Active malignancy or history of cancer (mitogenic risk)
- ·Pregnancy / lactation (no safety data)
- ·Hypoglycemia disorders
SS-31
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to peptide
Relative Contraindications
IGF-DES
- ·Diabetes mellitus (unpredictable glucose effects)
- ·Renal or hepatic impairment (clearance unknown)
- ·Edema-prone conditions (heart failure, nephrotic syndrome)
SS-31
- ·None established
05Administration Protocol
Parameter
IGF-DES
SS-31
1. Research context only
Des(1-3)IGF-1 has no approved human protocol. All administration details are derived from animal or in vitro research and should not be construed as medical guidance.
Add bacteriostatic water per label. Light-protected handling.
2. Reconstitution (if lyophilized)
Sterile water or bacteriostatic water per research protocol. Gently swirl; do not shake. Store reconstituted peptide at 2–8 °C.
SQ — abdomen or thigh. Rotate sites.
3. Injection site
Subcutaneous (abdomen, thigh) or intramuscular (deltoid, vastus lateralis). Local injection to target tissue (e.g., muscle group) may enhance regional uptake.
Morning fasted; pre-workout for exercise-augmented mitochondrial stress.
4. Timing
Frequency and timing vary by research design. Post-exercise or fasted state may theoretically enhance muscle uptake.
Lyophilised: refrigerate, light-protected. Reconstituted: refrigerate ≤30 days.
5. Needle gauge
27–31G insulin syringe for subcutaneous; 25–27G for intramuscular.
29–31G, 4–8 mm insulin syringe.
6. Monitoring
Glucose monitoring essential (hypoglycemia risk). No established IGF-1 or safety labs for human use.
—
06Stack Synergy
IGF-DES
+ BPC-157
ModerateDes(1-3)IGF-1 promotes myoblast differentiation and protein synthesis, while BPC-157 enhances tissue repair, angiogenesis, and collagen synthesis. Both act on distinct pathways (IGF1R vs gastric pentadecapeptide mechanisms) to support muscle recovery and connective tissue integrity. Synergy is mechanistic but lacks direct co-administration studies.
- Des(1-3)IGF-1
- Research dose post-workout (local IM)
- BPC-157
- 250–500 mcg SQ, daily or twice daily
- Frequency
- Daily or per research protocol
- Primary benefit
- Accelerated muscle repair, enhanced hypertrophy, connective tissue support
+ TB-500
ModerateTB-500 (Thymosin Beta-4 fragment) promotes cell migration, angiogenesis, and wound healing via actin regulation. Des(1-3)IGF-1 drives protein synthesis and myoblast proliferation. Combined, these peptides may synergistically enhance muscle recovery, repair, and hypertrophy through complementary anabolic and regenerative pathways. No direct human co-administration data.
- Des(1-3)IGF-1
- Research dose post-workout (local IM)
- TB-500
- 2–5 mg SQ, 2× weekly
- Frequency
- Per research cycle
- Primary benefit
- Muscle hypertrophy, injury recovery, vascular support
SS-31
+ MOTS-c
ModerateSS-31 and MOTS-c address mitochondrial decline through complementary axes. SS-31 protects existing mitochondrial structure (cardiolipin binding, cristae stabilisation). MOTS-c upregulates AMPK/PGC-1α, triggering biogenesis of new mitochondria. Together they pair preservation with renewal — anecdotally favoured in healthspan and post-cardio-event recovery protocols.
- SS-31
- 5–10 mg SQ · daily morning
- MOTS-c
- 5 mg SQ · 2× per week pre-workout
- Primary benefit
- Mitochondrial preservation + biogenesis